Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
ENPP1 acts as a negative regulator of the cGAS-STING pathway through the hydrolysis of 2'3'-cGAMP. Inhibitors of ENPP1 are regarded as promising agents for stimulating the immune response in cancer immunotherapy. This study describes the identification and optimization of imidazo[1,2-]pyrazine derivative as a highly potent and selective ENPP1 inhibitor. Compound demonstrated substantial inhibitory activity against ENPP1 with an IC value of 5.70 or 9.68 nM while showing weak inhibition against ENPP2 and ENPP3. Furthermore, compound was shown to enhance the mRNA expression of cGAMP-induced STING pathway downstream target genes, such as , , and 6. pharmacokinetic and antitumor studies showed promising results, with not only exhibiting efficient pharmacokinetic properties but also enhancing the antitumor efficacy of the anti-PD-1 antibody. Treatment with (80 mg/kg) combined with anti-PD-1 antibody achieved a tumor growth inhibition rate of 77.7% and improved survival in a murine model.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1021/acs.jmedchem.4c01634 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
ENPP1 inhibitor with ultralong drug-target residence time as an innate immune checkpoint blockade cancer therapy.
Cell Rep Med
August 2025
Department of Biochemistry, Stanford University, Stanford, CA 94305, USA; ChEM-H Institute, Stanford University, Stanford, CA 94305, USA; Arc Institute, Palo Alto, CA 94304, USA. Electronic address:
Only one in five patients respond to immune checkpoint inhibitors, which primarily target adaptive immunity. Ectonucleotide pyrophosphatase/phophodiesterase 1 (ENPP1), the dominant hydrolase of 2'3'-cyclic-GMP-AMP (cGAMP) that suppresses downstream stimulator of interferon genes (STING) signaling, has emerged as a promising innate immunotherapy target. However, existing ENPP1 inhibitors have been optimized for prolonged systemic residence time rather than effective target inhibition within tumors.
View Article and Find Full Text PDFAdvances in STING Pathway Modulation for Cancer and Immunotherapy: A Comprehensive Review of Preclinical and Clinical Studies (2020-2024).
Cancer Biother Radiopharm
August 2025
Department of Pharmacology, St.Pauls College of Pharmacy, Hyderabad, India.
In cancer immunotherapy, the stimulator of interferon genes (STING) pathway regulation has become a promising new approach, offering potential solutions to overcome limitations of current treatments. Recent advances have revealed intricate mechanisms of STING activation and regulation, leading to the development of novel small-molecule agonists with improved properties. Preclinical studies have shown that STING agonists can convert "cold" tumors to "hot" ones, enhancing immune cell infiltration and overcoming resistance to checkpoint inhibitors.
View Article and Find Full Text PDFExpression of ENPP1 in Testicular Germ Cell Tumors: Exploring Its Role in the Pathobiology of Distinct Histotypes and in Prognosis.
Pathobiology
July 2025
Department of Pathology, Portuguese Oncology Institute of Porto (IPOP), Portuguese Oncology Institute of Porto (IPO Porto)/Porto Comprehensive Cancer Center Raquel Seruca (Porto.CCC), Porto, Portugal.
Introduction: Testicular germ cell tumors (TGCTs) are the most common solid malignancies among young men. Despite good response to cisplatin-based chemotherapy, side effects negatively affect quality of life. Recent development of ecto-nucleotide pyrophosphatase/phosphodiesterase 1 (ENPP1) inhibitors opens opportunity for targeted therapy, but ENPP1 expression in TGCTs has not been characterized.
View Article and Find Full Text PDFIdentification of 5,7-Dihydro-6-pyrrolo[2,3-]pyrimidin-6-one Derivatives as ENPP1 Inhibitors for STING Pathway-Mediated Immunotherapy.
J Med Chem
August 2025
Department of Chemistry, Sogang University, 35, Baekbeom-ro, Mapo-gu, Seoul 04107, Republic of Korea.
A novel small-molecule ENPP1 inhibitor, compound featuring a pyrrolopyrimidinone core, was identified. Compound exhibited potent ENPP1 inhibition with an IC of 14.68 nM and effectively activated the STING pathway in cell lines.
View Article and Find Full Text PDFDual ENPP1/ATM depletion blunts DNA damage repair boosting radioimmune efficacy to abrogate triple-negative breast cancer.
Signal Transduct Target Ther
June 2025
Solid Tumors Program. Division of Oncology, Center for Applied Medical Research (CIMA)-University of Navarra, Pamplona, Spain.
The ATP-hydrolytic ectoenzyme ENPP1 has been implicated in the metastasis and recurrence in triple-negative breast cancer (TNBC), primarily by contributing to tumor cell survival and treatment resistance. However, the precise mechanisms remain unclear. In a model of local recurrence (LR), circulating tumor cells (CTC) engrafting in the post-resection tumor bed developed a radioresistant phenotype linked to an ENPP1-gene signature which was also identified in TNBC patients, suggesting ENPP1´s role in genome integrity.
View Article and Find Full Text PDF